IBIO: Developing a Long Uptrend and Broader Investor Interest?
WRDC6B's Blog
12 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
On Friday, January 14, 2011, iBio, Inc. (NYSE Amex: IBIO) opened for the day's trading at $4.20, up $0.30 from its January 13 close of $3.90, on stronger investor interest. The stock went on to form a new high, closing at $4.91 on volume of 325,356 shares - A fantastic 25.90% increase! In fact, IBIO captured the number two position on the American Stock Exchange's highest percentage gainers for the day.
As today has come to a close, IBIO followers commence a three day wait in anticipation of the stock's next trading day on January 18. In the meantime, anyone wanting to step aboard this train needs to act quickly to learn more about what makes this biopharmaceutical company a stand-out before it leaves the station again - Possibly headed for higher altitudes and as-yet-unexplored territory. Visit www.ibioinc.com for more information. In closing, this writer offers a respectful salute to the memory of Dr. Martin Luther King, Jr. on Monday, January 17, 2011.
As today has come to a close, IBIO followers commence a three day wait in anticipation of the stock's next trading day on January 18. In the meantime, anyone wanting to step aboard this train needs to act quickly to learn more about what makes this biopharmaceutical company a stand-out before it leaves the station again - Possibly headed for higher altitudes and as-yet-unexplored territory. Visit www.ibioinc.com for more information. In closing, this writer offers a respectful salute to the memory of Dr. Martin Luther King, Jr. on Monday, January 17, 2011.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.